Focusing on plasma GFAP alone, its levels showed a gradual increase along the three cohorts, with the highest concentration in patients with AD, thereby allowing a good biological interpretation of a gradual rise of this biomarker along the progressing neuropathological process. The gene discussed is GFAP; the disease is Alzheimer disease.